发明名称 |
Method for treating gefitinib resistant cancer |
摘要 |
The present invention is directed to methods for the treatment of gefitinib and/or erlotinib resistant cancer. An individual with cancer is monitored for cancer progression following treatment with gefitinib and/or erlotinib. Progression of the cancer is indicative that the cancer is resistant to gefitinib and/or erlotinib. Once progression of cancer is noted, the subject is administered a pharmaceutical composition comprising an irreversible epidermal growth factor receptor (EGFR) inhibitor. In preferred embodiments, the irreversible EGFR inhibitor is EKB-569, HKI-272 and HKI-357. |
申请公布号 |
AU2006210572(A2) |
申请公布日期 |
2006.08.10 |
申请号 |
AU20060210572 |
申请日期 |
2006.02.02 |
申请人 |
THE GENERAL HOSPITAL CORPORATION;WYETH |
发明人 |
NADIA G. GODIN-HEYMANN;DANIEL HABER;EUNICE L. KWAK;DAPHNE WINIFRED BELL;RAFFAELLA SORDELLA;JEFFREY E. SETTLEMAN;SRIDHAR KRISHNA RABINDRAN |
分类号 |
A61K31/00 |
主分类号 |
A61K31/00 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|